$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000162828016020671 Filed on November 03, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$2.362M	$1.759M	$2.045M
YoY Change	12.91%	-13.99%	15.87%
Cost Of Revenue	$120.0K	$18.08M	$120.0K
YoY Change	20.0%	14966.67%	33.33%
Gross Profit	$2.240M	-$16.32M	$1.930M
YoY Change	12.56%	-945.6%	14.88%
Gross Profit Margin	94.83%	-927.8%	94.38%
Selling, General & Admin	$3.610M	$4.680M	$2.770M
YoY Change	22.79%	68.95%	1.84%
% of Gross Profit	161.16%		143.52%
Research & Development	$9.390M	$6.781M	$4.001M
YoY Change	-23.6%	69.48%	7.98%
% of Gross Profit	419.2%		207.31%
Depreciation & Amortization	$50.00K	$50.00K	$40.00K
YoY Change	25.0%	25.0%	0.0%
% of Gross Profit	2.23%		2.07%
Operating Expenses	$13.01M	$6.781M	$4.001M
YoY Change	-14.63%	69.48%	7.98%
Operating Profit	-$10.76M	-$27.79M	-$4.844M
YoY Change	-18.75%	473.68%	1.91%
Interest Expense	-$570.0K	$657.0K	$827.0K
YoY Change	-25.0%	-20.56%	-11.45%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$556.0K	-$699.0K
YoY Change	-100.0%	-20.46%	-15.49%
Pretax Income	-$11.33M	-$28.35M	-$5.540M
YoY Change	-15.82%	411.73%	-0.72%
Income Tax
% Of Pretax Income
Net Earnings	-$11.34M	-$28.35M	-$5.543M
YoY Change	-15.79%	411.37%	-0.67%
Net Earnings / Revenue	-479.89%	-1611.43%	-271.05%
Basic Earnings Per Share
Diluted Earnings Per Share	-$402.5K	-$1.073M	-$215.7K
COMMON SHARES
Basic Shares Outstanding	140.5M shares	129.5M shares	129.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$44.50M	$53.40M	$93.50M
YoY Change	-45.86%	-42.89%	71.25%
Cash & Equivalents	$26.04M	$20.67M	$28.66M
Short-Term Investments	$18.40M	$32.70M	$64.80M
Other Short-Term Assets	$1.300M	$1.400M	$800.0K
YoY Change	8.33%	75.0%	14.29%
Inventory
Prepaid Expenses
Receivables	$2.459M	$1.857M	$2.318M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$48.20M	$56.65M	$96.61M
YoY Change	-43.63%	-41.36%	69.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$413.0K	$406.0K	$315.5K
YoY Change	48.56%	28.7%	-22.56%
Goodwill	$9.000M	$8.982M	$8.982M
YoY Change	0.2%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$3.000K	$3.000K	$56.03K
YoY Change	-94.12%	-94.65%	-27.76%
Total Long-Term Assets	$9.551M	$9.544M	$9.506M
YoY Change	0.92%	0.4%	-14.37%
TOTAL ASSETS
Total Short-Term Assets	$48.20M	$56.65M	$96.61M
Total Long-Term Assets	$9.551M	$9.544M	$9.506M
Total Assets	$57.75M	$66.19M	$106.1M
YoY Change	-39.19%	-37.62%	55.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.883M	$5.056M	$2.569M
YoY Change	39.51%	96.81%	8.34%
Accrued Expenses	$2.725M	$2.324M	$1.874M
YoY Change	40.9%	24.02%	-3.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.939M	$5.104M	$4.860M
YoY Change	7.21%	5.01%	-11.97%
Total Short-Term Liabilities	$13.55M	$12.48M	$9.303M
YoY Change	25.92%	34.19%	-5.4%
LONG-TERM LIABILITIES
Long-Term Debt	$14.92M	$15.80M	$20.67M
YoY Change	-23.71%	-23.56%	-12.2%
Other Long-Term Liabilities	$18.00K	$41.00K	$148.7K
YoY Change	-87.05%	-72.44%	-20.64%
Total Long-Term Liabilities	$14.94M	$15.84M	$20.82M
YoY Change	-24.16%	-23.91%	-12.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.55M	$12.48M	$9.303M
Total Long-Term Liabilities	$14.94M	$15.84M	$20.82M
Total Liabilities	$28.49M	$28.32M	$30.12M
YoY Change	-6.47%	-5.97%	-10.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$898.9M	-$887.6M	-$825.1M
YoY Change	7.2%	7.58%	6.62%
Common Stock	$929.7M	$927.0M	$902.5M
YoY Change	2.79%	2.71%	103369.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.524M	$1.524M	$1.524M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	1.223M shares	1.223M shares	1.223M shares
Shareholders Equity	$29.45M	$37.87M	$75.99M
YoY Change
Total Liabilities & Shareholders Equity	$57.75M	$66.19M	$106.1M
YoY Change	-39.19%	-37.62%	55.57%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$11.34M	-$28.35M	-$5.543M
YoY Change	-15.79%	411.37%	-0.67%
Depreciation, Depletion And Amortization	$50.00K	$50.00K	$40.00K
YoY Change	25.0%	25.0%	0.0%
Cash From Operating Activities	-$9.390M	-$7.580M	-$4.480M
YoY Change	-13.54%	69.2%	115.38%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	-$10.00K	-$40.00K
YoY Change		-75.0%	300.0%
Acquisitions
YoY Change
Other Investing Activities	$14.12M	$20.24M	$2.800M
YoY Change	-9.83%	622.86%	305.8%
Cash From Investing Activities	$14.06M	$20.22M	$2.760M
YoY Change	-10.22%	632.61%	305.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	690.0K	-620.0K	-1.110M
YoY Change	-286.49%	-44.14%	35.37%
NET CHANGE
Cash From Operating Activities	-9.390M	-7.580M	-4.480M
Cash From Investing Activities	14.06M	20.22M	2.760M
Cash From Financing Activities	690.0K	-620.0K	-1.110M
Net Change In Cash	5.360M	12.02M	-2.830M
YoY Change	20.99%	-524.73%	27.48%
FREE CASH FLOW
Cash From Operating Activities	-$9.390M	-$7.580M	-$4.480M
Capital Expenditures	-$60.00K	-$10.00K	-$40.00K
Free Cash Flow	-$9.330M	-$7.570M	-$4.440M
YoY Change	-14.09%	70.5%	114.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4217000	USD
	cris	Issuance Of Common Stock To Licensees IssuanceOfCommonStockToLicensees	23968000	USD
	cris	Issuance Of Common Stock To Licensees IssuanceOfCommonStockToLicensees	17989000	USD
	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	plan
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	140549019	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
CY2015Q4	cris	Collaborative Arrangement Numberof Optional Additional Terms CollaborativeArrangementNumberofOptionalAdditionalTerms	3	term
CY2015Q4	cris	Collaborative Arrangement Option Fees Numberof Payments CollaborativeArrangementOptionFeesNumberofPayments	2	payment
CY2015	cris	Collaborative Arrangement Option Fees Total CollaborativeArrangementOptionFeesTotal	7500000	USD
CY2015	cris	Collaborative Arrangement Optional Additional Term CollaborativeArrangementOptionalAdditionalTerm	P1Y
	dei	Trading Symbol TradingSymbol	CRIS
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5056000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2106000	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1857000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-119000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-83000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1934000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2324000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	123000	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	115000	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1310000	USD
CY2016Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1637000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	28000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	26000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	903240000	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	925569000	USD
CY2015Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-100000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	200000	USD
CY2016Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	100000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-100000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	26492000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	22653000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	44000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	36000	USD
CY2015Q4	us-gaap	Assets Assets	94965000	USD
CY2016Q3	us-gaap	Assets Assets	66193000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	85501000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	56649000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	44000	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	32000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16000	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	49072000	USD
CY2016Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	32657000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	49100000	USD
CY2016Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	32684000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7747000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28659000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33091000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20671000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	20912000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-12420000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	130213224	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141217276	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128990378	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	139994430	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	1302000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	1412000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5488000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45456000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28376000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	357000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-238000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2800000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-249000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	339000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	265000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49079000	USD
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	6889000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1109000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	49021000	USD
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	29548000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	52441000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	123000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	141000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7100000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	17000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2772000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9712000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4684000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11743000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	8982000	USD
CY2016Q3	us-gaap	Goodwill Goodwill	8982000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	76000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-14000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	827000	USD
	us-gaap	Interest Expense InterestExpense	2537000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	657000	USD
	us-gaap	Interest Expense InterestExpense	2126000	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	252000	USD
CY2016Q3	us-gaap	Interest Payable Current InterestPayableCurrent	225000	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	128000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	252000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	101000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	325000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	30455000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	28323000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	94965000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66193000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10758000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12484000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4607000	USD
CY2016Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	5104000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19558000	USD
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15798000	USD
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	49100000	USD
CY2016Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	32684000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	62029000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2058000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-22089000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	16062000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19028000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26424000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-5543000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45520000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-28345000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49077000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4844000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43235000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-27789000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-47276000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	249000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	347000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	51000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	139000	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	41000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-699000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2285000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-556000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1801000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	95595000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	50485000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	269000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1204000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1437000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64619000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	203000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1161000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	73521000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	66816000	USD
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	19000	USD
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	278000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	406000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2793000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	3219000	USD
CY2015Q3	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-248000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-212000	USD
CY2016Q3	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-58000	USD
	us-gaap	Royalty Expense RoyaltyExpense	303000	USD
CY2015Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4001000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14658000	USD
CY2016Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6781000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	22431000	USD
CY2015Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	24348000	USD
CY2016Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	17989000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	17989000	USD
CY2015Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	153000	USD
CY2016Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	153000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-838536000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-887613000	USD
CY2015Q3	us-gaap	Revenues Revenues	2045000	USD
	us-gaap	Revenues Revenues	5786000	USD
CY2016Q3	us-gaap	Revenues Revenues	1759000	USD
	us-gaap	Revenues Revenues	5165000	USD
CY2015Q3	us-gaap	Royalty Expense RoyaltyExpense	116000	USD
CY2016Q3	us-gaap	Royalty Expense RoyaltyExpense	94000	USD
	us-gaap	Royalty Expense RoyaltyExpense	278000	USD
CY2015Q3	us-gaap	Royalty Revenue RoyaltyRevenue	2293000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	5998000	USD
CY2016Q3	us-gaap	Royalty Revenue RoyaltyRevenue	1817000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	5403000	USD
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	901000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2875000	USD
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1630000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3311000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.63
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.019
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.018
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.015
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.08
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9200000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15487348	shares
CY2016Q3	us-gaap	Share Price SharePrice	1.76
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3900000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2100000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	64510000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	37870000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2016Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524000	USD
CY2016Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1524000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	128392413	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	121634415	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	132065947	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	130122698	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Nature of Business</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s most advanced drug candidate is CUDC-907, which is being investigated in clinical studies in patients with diffuse large B-cell lymphoma and solid tumors.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene. In September 2016, the Company entered into an amendment to this agreement, pursuant to which Aurigene received </font><font style="font-family:inherit;font-size:10pt;">10,208,333</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock in lieu of receiving up to </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;"> of milestone and other payments from Curis (see Note 4(b)). </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaboration comprises multiple programs, in which Curis has the option to exclusively license each program, including data, intellectual property and compounds associated with each respective program, once a development candidate is nominated within that program. In October 2015, the Company exercised options to license the first </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs under this collaboration. The first licensed program is focused on the development of orally-available small molecule antagonists of programmed death-1 (PD1) and V-domain Ig suppressor of T-cell activation (VISTA) pathways in the immuno-oncology field. The Company has named CA-170, a programmed death ligand-1 (PDL1)/VISTA antagonist, as the development candidate from this program. The second licensed program is focused on orally-available small molecule inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4) enzyme in the precision oncology field and the Company has named CA-4948 as the development candidate from this program. In addition, in October 2015, the Company selected a third program for further development under the collaboration, the second preclinical program within the immuno-oncology field, which is focused on evaluating small molecule antagonists of PD1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM3) pathways, including small molecules that target PDL1 and TIM3. In October 2016, the Company exercised its option to license this third program, and designated CA-327 as the development candidate. </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also party to a collaboration with F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under which Roche and Genentech are commercializing Erivedge</font><font style="font-family:inherit;font-size:9pt;">®</font><font style="font-family:inherit;font-size:10pt;"> (vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor, in advanced basal cell carcinoma, or BCC. In addition to BCC, Roche and Genentech are separately conducting studies of Erivedge in other diseases, including in idiopathic pulmonary fibrosis and myelofibrosis.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s proprietary small molecule compounds also include CUDC-427, an orally-available, small molecule antagonist of inhibitor of apoptosis, or IAP proteins, and CUDC-305, an orally-available, small molecule antagonist of Heat Shock Protein 90.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the United States Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to advance and expand its research and development programs; the Company’s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties’ collaboration agreement; the Company’s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company’s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.à.r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it receives and makes under its current and potential future collaborations. The results of the Company’s operations may vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; Aurigene’s ability to successfully discover and develop preclinical programs under the Company’s collaboration with Aurigene, as well as the Company’s decision to exclusively license and further develop programs under this collaboration; Roche and Genentech’s ability to successfully commercialize Erivedge; positive results in Roche and Genentech’s ongoing clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company anticipates that its existing cash, cash equivalents and investments at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> should enable it to maintain current and planned operations into the second half of 2017. The Company’s ability to continue funding its planned operations beyond this period is dependent upon, among other things, its ability to control expenses and its ability to raise additional funds through equity or debt financings, the success of its collaboration with Genentech, including its receipt of additional contingent cash payments under this collaboration, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of such events is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-020671-index-headers.html	Edgar Link	pending
0001628280-16-020671-index.html	Edgar Link	pending
0001628280-16-020671.txt	Edgar Link	pending
0001628280-16-020671-xbrl.zip	Edgar Link	pending
cris-20160930.xml	Edgar Link	completed
cris-20160930.xsd	Edgar Link	pending
cris-20160930_cal.xml	Edgar Link	unprocessable
cris-20160930_def.xml	Edgar Link	unprocessable
cris-20160930_lab.xml	Edgar Link	unprocessable
cris-20160930_pre.xml	Edgar Link	unprocessable
cris-9302016x10q3.htm	Edgar Link	pending
cris-9302016xq3ex101.htm	Edgar Link	pending
cris-9302016xq3ex102.htm	Edgar Link	pending
cris-9302016xq3ex103.htm	Edgar Link	pending
cris-9302016xq3ex104.htm	Edgar Link	pending
cris-9302016xq3ex311.htm	Edgar Link	pending
cris-9302016xq3ex312.htm	Edgar Link	pending
cris-9302016xq3ex321.htm	Edgar Link	pending
cris-9302016xq3ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelineupdatedv2a01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2016 Q4 Form 10-Q Financial Statement

#000162828016020671 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2016 Q4 Form 10-Q Financial Statement

#000162828016020671 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris